Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Drugs of Today (Barcelona, Spain : 1998)|February 27, 2023
Monoclonal antibodies for treatment of osteoporosisKveta Kroupova, Vladimir Palicka, Jan RosaVnitrni Lekarstvi|December 1, 2016
[Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis]Jan Štěpán, Jan Rosa, Karel PavelkaHypertension Research : Official Journal of the Japanese Society of Hypertension|November 26, 2010
Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapyJan Rosa, Ivan Raska, Dan Wichterle, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|February 27, 2010
Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomyOndrej Petrák, Branislav Strauch, Tomás Zelinka, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 14, 2025
A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosisLothar Seefried, Serge Ferrari, Dénes Páll, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 25, 2026
Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phaseSerge Ferrari, Lothar Seefried, Dénes Páll, et al.Heliyon|October 15, 2024
Identification of kidney cell types in scRNA-seq and snRNA-seq data using machine learning algorithmsAdam Tisch, Siddharth Madapoosi, Stephen Blough, et al.Journal of Hypertension|November 7, 2014
Hyperresponders vs. nonresponder patients after renal denervation: do they differ?Alexandre Persu, Michel Azizi, Yu Jin, et al.The Journal of Clinical Endocrinology and Metabolism|September 7, 2024
Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12Bente Langdahl, Yoon-Sok Chung, Rafal Plebanski, et al.Pageof 2